Table 1.
Characteristics of Mothers Who Received Seasonal Trivalent Influenza Vaccine (IIV3), by Human Immunodeficiency Virus (HIV) Status, and Their Infants
| Characteristica | HIV-Uninfected Cohort |
HIV-Infected Cohort |
||
|---|---|---|---|---|
| Subjects, No. | Value | Subjects, No. | Value | |
| Mothers | ||||
| Age, y | 98 | 26.4 ± 5.2 | 100 | 27.2 ± 4.9 |
| Body mass indexb | 57 | 29.1 ± 4.6 | 81 | 29.2 ± 5.0 |
| Gestational age, wk | 98 | 26.8 ± 4.6 | 100 | 27.6 ± 3.9 |
| Primigravidc | 98 | 30 (30.6) | 99 | 18 (18.2) |
| Time after vaccination, d | ||||
| Of first postvaccination immunogenicity visitd | 60 | 30.6 ± 2.2 | 70 | 30.1 ± 2.0 |
| Of delivery immunogenicity visitd | 43 | 87.9 ± 37.6 | 61 | 78.7 ± 32.0 |
| Of postpartum wk 24 immunogenicity visitd | 50 | 248.6 ± 40.2 | 60 | 243.9 ± 32.1 |
| CD4+ T-cell count | ||||
| <200 cells/µL | NA | NA | 99 | 7 (7.1) |
| 200–350 cells/µL | NA | NA | 99 | 29 (29.3) |
| 351–500 cells/µL | NA | NA | 99 | 33 (33.3) |
| >500 cells/µL | NA | NA | 99 | 30 (30.3) |
| HIV load ≤40 copies/mL | NA | NA | 98 | 18 (18.4) |
| Receiving antiretroviral therapye | NA | NA | 100 | 80 (80.0) |
| Infants | ||||
| Births <370/7 | 69 | 1 (1.5) | 76 | 5 (6.6) |
| Birth weight, kg | 69 | 3.2 (2.3–4.0) | 75 | 3.0 (2.1–4.3) |
| Low birth weight | 69 | 2 (2.9) | 76 | 3 (4.0) |
| Time between vaccination and birth, d | 69 | 84.4 ± 36.6 | 76 | 77.5 ± 30.2 |
| Age, d | ||||
| At first infant antibody measurementd | 39 | 5 (3–7) | 56 | 5 (3–7) |
| At 8-wk antibody measurementd | 50 | 56 (56–63) | 56 | 57 (56–63) |
| At 16-wk antibody measurementc | 49 | 112 (112–119) | 57 | 113 (112–119) |
| At 24-wk antibody measurementd | 44 | 169 (168–175) | 53 | 169 (168–175) |
Data are mean ± SD, no. (%) of women, or median (range).
Abbreviation: NA, not applicable.
a Data for mothers were recorded at the time of IIV3 receipt, unless otherwise indicated.
b Body mass index is defined as the weight in kilograms divided by the height in meters squared.
c P = .042.
d Only participants who had their schedule visits within the study periods were included in the immunogenicity analyses.
e Includes participants receiving antiretroviral therapy for prevention of mother-to-child HIV transmission and those receiving highly active antiretroviral treatment.